Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada

Link to Full Article Patent allowances cover various aspects of the Company’s phage program and lead product candidate, AP-SA01 Company to host bacteriophage Key Opinion Leader meeting and live webcast on Wednesday, June 26 MARINA DEL REY, Calif., June 3, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage […]

Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient

Link to Full Article Armata’s bacteriophage, AP-PA01, used to treat multidrug-resistant Pseudomonas aeruginosa infection Paper appears in the peer-reviewed journal Infection Company to host bacteriophage Key Opinion Leader meeting and live webcast on Wednesday, June 26 MARINA DEL REY, Calif, May 28, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely […]

Health Economic Model Published in Advances in Therapy Demonstrates Reduced Cost and Decreased Hospital Stay with the RECELL® System

Link to Full Article Real world experience found that the RECELL System could save one US Burn Center up to USD $28MM annually Valencia, Calif., USA, and Melbourne, Australia, 16 May 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY) announced today that the health economic model of the U.S. burn care pathway, developed in collaboration […]

AVITA Medical Appoints Interim CFO

Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 15 May 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company,  announced today that Dale A. Sander is resigning as Chief Financial Officer (CFO) to spend more time with his family on the east coast, effective immediately. Tim Rooney, AVITA’s Chief […]

Destiny Pharma appoints NOMAD and Joint Broker

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Appointment of NOMAD and Joint Broker Brighton, United Kingdom – 9 May 2019 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs which address the global problem of anti-microbial resistance (AMR), announces the appointment of finnCap Ltd as Nominated […]

C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.

Link to Article Shares of the combined company to commence trading on the NYSE American exchange under the new symbol “ARMP” on May 10, 2019 Completed $10 million concurrent financing Ongoing collaboration with Merck to develop proprietary synthetic phage candidates MARINA DEL REY, Calif., May 9, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage […]

AmpliPhi Biosciences Announces Stockholder Approval of Business Combination with C3J Therapeutics

Link to Article SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that its stockholders voted to approve the proposals required to complete the business combination with C3J Therapeutics at a special meeting of AmpliPhi Biosciences stockholders held earlier today. Approximately […]

Global Kinetics Corporation’s PKG® Provides Clinically Meaningful Improvement in Symptom Assessment, Management, Medication Optimization, and PatientClinician Conversations in Parkinson’s Disease

Link to Full Article Data Recently Presented at the 2019 American Academy of Neurology’s Annual Meeting APPRISE Clinical Study Continues Enrollment at 10 Movement Disorder Clinics in the U.S. PORTSMOUTH, N.H. and LONDON and MELBOURNE, Australia, May 07, 2019 (GLOBE NEWSWIRE) — Global Kinetics today reported data that was recently presented at poster presentation sessions […]

PROACTIVEINVESTORS interview with CEO, Dr Sarah Howell re the dosing of Arecor’s first patient in its Phase I clinical trial of its rapid-acting insulin product candidate, AT247, for the improved treatment of diabetes.

Link to Full Article Arecor, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, announces the initiation of its AT247 Phase I clinical trial and an important next step in the Company’s strategy to develop even faster acting insulins targeted at […]

ULTRA-RAPID ACTING INSULIN PRODUCT CANDIDATE AT247 FOR DIABETES

Link to Full Article Cambridge, UK., 7th May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces dosing of the first patient in its Phase I clinical trial for its ultra-rapid acting […]